Previous 10 | Next 10 |
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Results Earnings Conference Call May 06, 2021, 5:00 pm ET Company Participants Glenn Schulman - Senior Vice President, Corporate Communications and Investor Relations Peter Greenleaf - Chief Executive Officer, Director Max Colao - Chief Commercial O...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today. ...
Aurinia Pharma (AUPH): Q1 GAAP EPS of -$0.40 misses by $0.02.Revenue of $0.91M (+2175.0% Y/Y) misses by $2.12M.Shares -1.13%.Press Release For further details see: Aurinia Pharma EPS misses by $0.02, misses on revenue
- Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS™ as the first approved oral therapy for lupus nephritis (LN) - - Over 250 patient start forms received by the end of the first quarter - - Cash and cash equivalents, a...
Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...
Aurinia Pharmaceuticals (AUPH) rose 5.5% in premarket trading on some speculation about potential takeover interest.AstraZeneca (AZN), GlaxoSmithKline (GSK) are speculated to be interested in Aurinia, according to the London Times.Recall Jan. 25, Aurinia shares jump on voclosp...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded at a new 52-week low today of $11.61. Approximately 3.9 million shares have changed hands today, as compared to an average 30-day volume of 3.2 million shares. Aurinia Pharmaceuticals Inc share prices have moved between a 52-week high of $...
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded today at $11.68, breaking its 52-week low. This new low was reached on approximately average trading volume as 3.9 million shares traded hands, while the average 30-day volume is approximately 3.2 million shares. Over the past ye...
Aurinia Pharmaceuticals (TSX:AUP) (NASDAQ:AUPH) is a biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company has commercially laun...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...